Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2023

Conditions
CirrhosisSplenectomyVenous ThrombosisHypertension, Portal
Interventions
DRUG

Apixaban 2.5 MG

From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.

DRUG

Dipyridamole 25Mg Tab

From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.

DRUG

subcutaneous Low Molecular Weight Heparin

From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.

Trial Locations (1)

225001

Clinical Medical College, Yangzhou University, Yangzhou

All Listed Sponsors
lead

Northern Jiangsu People's Hospital

OTHER